Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.96
-0.20 (-2.18%)
Mar 30, 2026, 10:47 AM EDT - Market open

Zevra Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
83.23-105.51-46.05-26.77-8.56
Depreciation & Amortization
4.056.391.010.940.26
Stock-Based Compensation
12.6314.915.954.292.44
Other Adjustments
-7521.74-0.333.2216.66
Change in Receivables
-11.986.87-9.08-6.771.05
Changes in Inventories
-1.31-8.870.210.15-
Changes in Accounts Payable
-15.59-3.611.133.13-1.11
Changes in Other Operating Activities
2.36-1.593.633.09-0.3
Operating Cash Flow
-1.6-69.67-33.54-18.7210.44
Capital Expenditures
-0.84--0.3-0.09-0.1
Sale of Property, Plant & Equipment
0.45----
Proceeds from Sale of Intangible Assets
150----
Purchases of Investments
-309.99-41.16-45.81-23.86-15.42
Proceeds from Sale of Investments
178.52559.121.33-
Payments for Business Acquisitions
---30.4-14.09-
Other Investing Activities
--6---
Investing Cash Flow
18.13-22.16-17.39-36.72-15.52
Long-Term Debt Issued
-58.9942.4312.8-
Long-Term Debt Repaid
--42.7-17.53--37.92
Net Long-Term Debt Issued (Repaid)
-16.2924.912.8-37.92
Issuance of Common Stock
12.4467.266.320.32158.24
Repurchase of Common Stock
---3.45-4.72-2.81
Net Common Stock Issued (Repurchased)
12.4467.262.88-4.4155.43
Other Financing Activities
-0.37-1.440.69-0.05-4.39
Financing Cash Flow
12.0682.1128.468.35113.11
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.030.450.040.2-
Net Cash Flow
28.62-9.26-22.42-46.88108.02
Free Cash Flow
-2.43-69.67-33.83-18.8110.34
FCF Margin
-2.29%-295.04%-123.20%-179.86%36.08%
Free Cash Flow Per Share
-0.04-1.51-0.95-0.550.35
Levered Free Cash Flow
71.91-96.89-5.48-21.53-102.07
Unlevered Free Cash Flow
-76.76-79.84-33.93-36.086.45
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q